Brian M. Forde

Brian M. Forde

Auto-generated profile, based on publicly available information

Brian M. Forde

Institute for Molecular Bioscience, The University of Queensland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
DODavid M. P. De Oliveira
David M. P. De Oliveira
BFBrian M. Forde
Brian M. Forde
TKTimothy J. Kidd
Timothy J. Kidd
PHPatrick Harris
Patrick Harris
MSMark Schembri
Mark Schembri
Mark Joseph WalkerMark Joseph Walker
Mark Joseph Walker
Antimicrobial-resistant ESKAPE ( E nterococcus faecium , S taphylococcus aureus , K lebsiella pneumoniae , A cinetobacter baumannii , P seudomonas aeruginosa , and E nterobacter species) pathogens represent a global threat to human health. The acquisition of antimicrobial resistance genes by ESKAPE pathogens has reduced the treatment options for serious infections, increased the burden of disease, and increased death rates due to treatment failure and requires a coordinated global response for antimicrobial resistance surveillance.

31 March 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
NPNicola K. Petty
Nicola K. Petty
NZNouri L. Ben Zakour
Nouri L. Ben Zakour
MSMitchell Stanton-Cook
Mitchell Stanton-Cook
ESElizabeth Skippington
Elizabeth Skippington
MTMakrina Totsika
Makrina Totsika
SBScott Beatson
Scott Beatson
Significance: Escherichia coli sequence type 131 (ST131) is a globally disseminated multidrug-resistant clone associated with human urinary tract and bloodstream infections. Here, we have used genome sequencing to map the temporal and spatial relationship of a large collection of E. coli ST131 strains isolated from six distinct geographical regions across the world. We show that E. coli ST131 strains are distinct from other extraintestinal pathogenic E. coli and arose from a single progenitor strain prior to the year 2000.

17 February 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EREliette Riboulet-Bisson
Eliette Riboulet-Bisson
MSMark H. J. Sturme
Mark H. J. Sturme
IJIan Jeffery
Ian Jeffery
MOMichelle M. O'Donnell
Michelle M. O'Donnell
BNB. Anne Neville
B. Anne Neville
RRR. Paul Ross
R. Paul Ross
Lactobacilli are Gram-positive bacteria that are a subdominant element in the human gastrointestinal microbiota, and which are commonly used in the food industry. Some lactobacilli are considered probiotic, and have been associated with health benefits. However, there is very little culture-independent information on how consumed probiotic microorganisms might affect the entire intestinal microbiota. We therefore studied the impact of the administration of Lactobacillus salivarius UCC118, a microorganism well characterized for its probiotic properties, on the composition of the intestinal microbiota in two model animals. UCC118 has anti-infective activity due to production of the bacteriocin Abp118, a broad-spectrum class IIb bacteriocin, which we hypothesized could impact the microbiota. Mice and pigs were administered wild-type (WT) L. salivarius UCC118 cells, or a mutant lacking bacteriocin production. The microbiota composition was determined by pyrosequencing of 16S rRNA gene amplicons from faeces. The data show that L. salivarius UCC118 administration had no significant effect on proportions of major phyla comprising the mouse microbiota, whether the strain was producing bacteriocin or not. However, L. salivarius UCC118 WT administration led to a significant decrease in Spirochaetes levels, the third major phylum in the untreated pig microbiota. In both pigs and mice, L. salivarius UCC118 administration had an effect on Firmicutes genus members. This effect was not observed when the mutant strain was administered, and was thus associated with bacteriocin production. Surprisingly, in both models, L. salivarius UCC118 administration and production of Abp118 had an effect on Gram-negative microorganisms, even though Abp118 is normally not active in vitro against this group of microorganisms. Thus L. salivarius UCC118 administration has a significant but subtle impact on mouse and pig microbiota, by a mechanism that seems at least partially bacteriocin-dependent.

19 October 2015 in Scientific Reports
Verified
Journal Article
Open access
HZHosam M. Zowawi
Hosam M. Zowawi
BFBrian M. Forde
Brian M. Forde
MAMubarak Alfaresi
Mubarak Alfaresi
AAAbdulqadir Alzarouni
Abdulqadir Alzarouni
YFYasser Farahat
Yasser Farahat
DPDavid L Paterson
David L Paterson
Carbapenem resistant Enterobacteriaceae (CRE) pose an urgent risk to global human health. CRE that are non-susceptible to all commercially available antibiotics threaten to return us to the pre-antibiotic era. Using Single Molecule Real Time (SMRT) sequencing we determined the complete genome of a pandrug-resistant Klebsiella pneumoniae isolate, representing the first complete genome sequence of CRE resistant to all commercially available antibiotics. The precise location of acquired antibiotic resistance elements, including mobile elements carrying genes for the OXA-181 carbapenemase, were defined. Intriguingly, we identified three chromosomal copies of an ISEcp1-blaOXA-181 mobile element, one of which has disrupted the mgrB regulatory gene, accounting for resistance to colistin. Our findings provide the first description of pandrug-resistant CRE at the genomic level and reveal the critical role of mobile resistance elements in accelerating the emergence of resistance to other last resort antibiotics.

13 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
BFBrian M. Forde
Brian M. Forde
LRLeah W. Roberts
Leah W. Roberts
MPMinh-Duy Phan
Minh-Duy Phan
KPKate M. Peters
Kate M. Peters
BFBrittany A. Fleming
Brittany A. Fleming
SBScott Beatson
Scott Beatson
Recurrent urinary tract infections (rUTIs) are extremely common, with ~ 25% of all women experiencing a recurrence within 1 year of their original infection. Escherichia coli ST131 is a globally dominant multidrug resistant clone associated with high rates of rUTI. Here, we show the dynamics of an ST131 population over a 5-year period from one elderly woman with rUTI since the 1970s. Using whole genome sequencing, we identify an indigenous clonal lineage (P1A) linked to rUTI and persistence in the fecal flora, providing compelling evidence of an intestinal reservoir of rUTI. We also show that the P1A lineage possesses substantial plasmid diversity, resulting in the coexistence of antibiotic resistant and sensitive intestinal isolates despite frequent treatment. Our longitudinal study provides a unique comprehensive genomic analysis of a clonal lineage within a single individual and suggests a population-wide resistance mechanism enabling rapid adaptation to fluctuating antibiotic exposure.

1 August 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
ASAdam G Stewart
Adam G Stewart
DPDavid L Paterson
David L Paterson
BYBarnaby Young
Barnaby Young
DLDavid C. Lye
David C. Lye
JDJoshua S Davis
Joshua S Davis
GYGabriel Yan
Gabriel Yan
Carbapenems are recommended treatment for serious infections caused by AmpC-producing gram-negative bacteria but can select for carbapenem resistance. Piperacillin-tazobactam may be a suitable alternative. We enrolled adult patients with bloodstream infection due to chromosomal AmpC producers in a multicenter randomized controlled trial. Patients were assigned 1:1 to receive piperacillin-tazobactam 4.5 g every 6 hours or meropenem 1 g every 8 hours. The primary efficacy outcome was a composite of death, clinical failure, microbiological failure, and microbiological relapse at 30 days. Seventy-two patients underwent randomization and were included in the primary analysis population. Eleven of 38 patients (29%) randomized to piperacillin-tazobactam met the primary outcome compared with 7 of 34 patients (21%) in the meropenem group (risk difference, 8% [95% confidence interval {CI}, –12% to 28%]). Effects were consistent in an analysis of the per-protocol population. Within the subcomponents of the primary outcome, 5 of 38 (13%) experienced microbiological failure in the piperacillin-tazobactam group compared to 0 of 34 patients (0%) in the meropenem group (risk difference, 13% [95% CI, 2% to 24%]). In contrast, 0% vs 9% of microbiological relapses were seen in the piperacillin-tazobactam and meropenem arms, respectively. Susceptibility to piperacillin-tazobactam and meropenem using broth microdilution was found in 96.5% and 100% of isolates, respectively. The most common AmpC β-lactamase genes identified were blaCMY-2, blaDHA-17, blaCMH-3, and blaACT-17. No ESBL, OXA, or other carbapenemase genes were identified. Among patients with bloodstream infection due to AmpC producers, piperacillin-tazobactam may lead to more microbiological failures, although fewer microbiological relapses were seen. NCT02437045.